1. Clinical and genetic risk factors for aromatase inhibitor-associated arthralgia in breast cancer survivors
- Author
-
Romero, Sally AD, Su, H Irene, Satagopan, Jaya, Li, Q Susan, Seluzicki, Christina M, Dries, Annika, DeMichele, Angela M, and Mao, Jun J
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Estrogen ,Breast Cancer ,Cancer ,Aging ,Genetics ,Clinical Research ,Adult ,Aged ,Aged ,80 and over ,Aromatase Inhibitors ,Arthralgia ,Breast Neoplasms ,Cross-Sectional Studies ,Estradiol Dehydrogenases ,Female ,Genetic Markers ,Genetic Predisposition to Disease ,Humans ,Logistic Models ,Middle Aged ,Polymorphism ,Single Nucleotide ,Postmenopause ,Risk Factors ,Breast neoplasm ,Aromatase inhibitor ,Postmenopausal ,Risk factors ,Public Health and Health Services ,Oncology & Carcinogenesis ,Clinical sciences ,Oncology and carcinogenesis - Abstract
BackgroundArthralgia is a common and debilitating toxicity of aromatase inhibitors (AI) that leads to premature drug discontinuation. We sought to evaluate the clinical and genetic risk factors associated with AI-associated arthralgia (AIAA).MethodsWe performed a cross-sectional study among postmenopausal women with stage 0-III breast cancer who were prescribed a third-generation AI for adjuvant therapy. The primary outcome was patient-reported AIAA occurrence. We extracted and assayed germline DNA for single nucleotide polymorphisms (SNPs) of genes implicated in estrogen and inflammation pathways. Multivariable logistic regression models examined the association between demographic, clinical, and genetic factors and AIAA. Analyses were restricted to White participants.ResultsAmong 1049 White participants, 543 (52%) reported AIAA. In multivariable analyses, women who had a college education [Adjusted Odds Ratio (AOR) 1.49, 95% Confidence Interval (CI) 1.00-2.20], had a more recent transition into menopause (
- Published
- 2020